This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 6
  • /
  • Health Canada approves Rinvoq for the treatment of...

Health Canada approves Rinvoq for the treatment of adults with active psoriatic arthritis- AbbVie Canada

Read time: 1 mins
Published:17th Jun 2021
AbbVie Canada announced that Health Canada has approved Rinvoq (upadacitinib, 15 mg), an oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

“Psoriatic arthritis is a debilitating disease that can cause severe pain, restricted mobility, and lasting structural damage. The immune system creates inflammation that can lead to skin lesions associated with psoriasis, as well as pain, fatigue and stiffness in the joints,” said Dr. Proton Rahman, FRCPC, Clinical Rheumatologist at Eastern Health and University Research Professor at Memorial University. “Despite treatment advances, some people living with PsA do not achieve their treatment goals, which is why access to new therapies is so critical.

Condition: Psoriatic Arthritis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights